What Neovacs does

Neovacs is a French publicly traded biotechnology company founded in 1993 and headquartered in Paris, operating two distinct activities: proprietary drug R&D and minority investments in external biotech and medtech companies. The company's core technology is the proprietary Kinoïde® platform, an active immunotherapy approach that uses the patient's own immune system to regulate the harmful overproduction of cytokines. This platform underpins two lead candidates: Kinoïde® IFNα, targeting interferon alpha for the treatment of lupus, and Kinoïde® IL-4/IL-13/IgE, targeting interleukins and IgE for the treatment of allergies including asthma.

Both product candidates remain in development and are not yet commercially approved; Neovacs has not disclosed pricing, distribution, or go-to-market plans because commercialization would require regulatory approval (EMA, FDA) prior to launch. The company is pre-revenue from product sales, and its capital base is sustained through periodic equity and debt financings, including historical rounds led by Novartis Venture Fund, Bpifrance, Alpha Blue Ocean, and Debiopharm Innovation Fund, as well as an ORABSA 2023 bond program. As of the most recent disclosures, Neovacs operates with 11–50 employees and continues to present at scientific forums and seek public-research validation (e.g., ANR).

The investment activity, managed via an external project evaluation committee, is positioned as a complement to the proprietary Kinoïde® pipeline and is intended to give the company exposure to additional therapeutic and medical-device opportunities, though it is not the primary driver of the business. Neovacs' ultimate customer base—lupus and allergy patients—will only be accessible through healthcare provider and pharmaceutical partner channels once regulatory milestones are achieved.

Name

Neovacs

Legal name

Néovacs

Website

https://neovacs.fr

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

Neovacs is a French publicly traded biotech developing active immunotherapy vaccines using its proprietary Kinoïde® platform, targeting lupus (Kinoïde® IFNα) and allergies (Kinoïde® IL-4/IL-13/IgE), while also investing in external biotech and medtech companies.

Ownership category

akta.pro rank

Product category

Therapeutic Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH)

Keywords

• Therapeutic vaccines
• Biopharmaceutical development
• Cytokine immunotherapy
• Drug candidate pipeline
• Biotech equity investments

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Core offering

Neovacs develops therapeutic vaccines using its proprietary Kinoïde® active immunotherapy platform, with lead candidates targeting cytokine overproduction to treat lupus (Kinoïde® IFNα) and allergic conditions such as asthma (Kinoïde® IL-4/IL-13/IgE). The company also conducts equity investments in external biotech and medtech companies as a secondary activity alongside its internal R&D program.

Product overview

Neovacs is a French biotechnology company operating two distinct activities: Research and Development, and Investment. The company's product portfolio centers on its Kinoïde technology platform, an active immunotherapy approach that harnesses the patient's immune system to regulate harmful cytokine overproduction. The platform supports multiple drug candidates including Kinoïde® IFNα for lupus and Kinoïde® IL-4/IL-13/IgE for allergies. The company also invests in external BioTech and MedTech companies through its investment activity.

Differentiator

Problem solved

Functional benefit

Brands

• Kinoïde: Technological platform for active immunotherapy using the patient's immune system to regulate harmful cytokine overproduction. Used for drug candidates in lupus and allergies.

Products and services

• Kinoïde® IFNα Therapeutic vaccine candidate for lupus based on the proprietary Kinoïde® platform that induces the patient's immune system to produce polyclonal antibodies against interferon-alpha, a cytokine implicated in lupus pathogenesis.
• Kinoïde® IL-4/IL-13/IgE Therapeutic vaccine candidate designed to treat allergic conditions such as asthma by inducing polyclonal antibodies against the cytokines IL-4 and IL-13 and against immunoglobulin E (IgE), using the Kinoïde® active immunotherapy approach.
• Biotech and Medtech Investment Portfolio Equity investment activity targeting external biotechnology and medical-technology companies, conducted alongside Neovacs' internal R&D program to diversify exposure and capture returns from innovation in the life sciences sector.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• GSK (GlaxoSmithKline): Global pharmaceutical company commercializing Benlysta (belimumab) for systemic lupus erythematosus and a broad vaccines portfolio. Sets the commercial benchmark Neovacs' lupus program would need to beat and is a potential large-pharma partner/acquirer.
• CureVac: Public mRNA-vaccine biotech developing prophylactic and therapeutic vaccines, including oncology. Comparable as a public therapeutic-vaccine platform company, though much larger and focused on mRNA rather than cytokine-targeting active immunotherapy.
• Novavax: Public vaccine developer (Matrix-M adjuvant platform) focused on prophylactic infectious-disease vaccines. Comparable as a small-cap public vaccine-platform company facing commercialization and capital-raising challenges similar to Neovacs.
• AstraZeneca: Global pharma selling Saphnelo (anifrolumab) for lupus and pursuing a broad immunology pipeline. Represents direct competition in Neovacs' primary lupus indication and a likely comparator in any future clinical-trial design.
• BioNTech: Large public mRNA-vaccine company with both prophylactic and therapeutic (notably oncology) vaccine programs. Comparable as a public therapeutic-vaccine platform player, though at vastly greater scale and a different delivery modality than Neovacs' Kinoïde® conjugates.
• Sanofi: Global pharma co-developing Dupixent (dupilumab, anti-IL-4Rα) with Regeneron — the dominant targeted therapy in the same IL-4/IL-13 allergy/asthma pathway Neovacs' second candidate targets. Defines the efficacy benchmark for Neovacs' allergy program.

Emerging players

• Selecta Biosciences: Clinical-stage biotech (now part of Cartesian Therapeutics group activity) developing tolerogenic and immunomodulatory therapeutics using synthetic vaccine particles. Comparable mechanism of action to Neovacs' active-immunotherapy approach in autoimmune disease.
• Anokion: Swiss/US biotech developing antigen-specific immune tolerance therapies for autoimmune diseases (celiac, MS). Comparable to Neovacs in pursuing antigen-directed immune modulation as an alternative to broad immunosuppression or chronic biologics.
• BiondVax Pharmaceuticals: Israel-based clinical-stage biotech developing a multi-epitope universal flu vaccine using a recombinant protein approach. Comparable as a small, publicly listed therapeutic/prophylactic vaccine developer operating a single-platform technology model similar to Neovacs.

Direct peers

• Imcyse: Belgium-based clinical-stage biotech developing therapeutic vaccines (Imotope® platform) that target chronic autoimmune diseases such as type 1 diabetes and multiple sclerosis. Most directly comparable to Neovacs in modality (active immunotherapy for autoimmune indications) and stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/neovacs

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds9 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neovacs